Nebula Research & Development LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

Nebula Research & Development LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 4,584 shares of the biotechnology company's stock, valued at approximately $1,617,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cerity Partners LLC grew its stake in shares of United Therapeutics by 30.4% during the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Milestone Asset Management LLC grew its stake in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock valued at $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Korea Investment CORP increased its holdings in United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after purchasing an additional 789 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after buying an additional 50,291 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 1.5 %

NASDAQ:UTHR traded down $4.52 during trading hours on Thursday, hitting $298.57. 153,350 shares of the stock traded hands, compared to its average volume of 447,750. The firm has a market cap of $13.41 billion, a price-to-earnings ratio of 13.11, a PEG ratio of 0.97 and a beta of 0.63. The firm has a 50 day moving average price of $304.50 and a 200 day moving average price of $345.39. United Therapeutics Co. has a fifty-two week low of $236.65 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the business earned $6.17 EPS. Research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $896,950.62. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,500 shares of company stock valued at $24,472,050. Corporate insiders own 11.90% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a report on Monday, April 21st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $390.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.